Broadening the evidence base for rivaroxaban in heart failure.

30 April 2017 (13:20 - 13:35)

Organised by:

About the speaker

Professor Barry Greenberg

University of California San Diego, La Jolla (United States of America)

5 More presentations in this session

Presentation thumbnail

Introduction & remarks.

Professor N. Danchin (Paris, FR)

Presentation thumbnail

Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).

Professor M. Cowie (London, GB)

Presentation thumbnail

Options in thrombosis prevention and vascular health – What’s on the horizon?

Professor K. Fox (Edinburgh, GB)

Presentation thumbnail

Exploring new frontiers: is it time for a comorbidity-based approach in heart failure?

Doctor R. Mentz (Durham, US)

Presentation thumbnail

Q&A and closing remarks.

Professor M. Cowie (London, GB)

Access the full session

Session thumbnail

Management of co-morbidities in heart failure - Exploring new frontiers

The Event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

30 April 2017 13:20 CET

You may be interested in

Congress Session

Transforming heart failure care: unlocking new pathways

19 May 2025

Congress Presentation

Anticoagulation with direct-acting anticoagulants decreases the risk of cardiovascular adverse events in patients with heart failure and atrial fibrillation compared to acenocoumarol

29 June 2021

Congress Presentation

Stroke

22 May 2023

ESC Journals

66 Relative efficacy of sacubitril/valsartan, dapagliflozin and vericiguat: a systematic review and network meta-analysis

17 December 2020

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources